Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer’s disease

New York, NY – November 3, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) announced today that it has received regulatory approval from the Ethics Committee in Australia to initiate a Phase 2a clinical trial of its proprietary compound, ANAVEX 2-73, as well as ANAVEX PLUS, the combination of ANAVEX 2-73…